Salute e Benessere

First participants enrolled in first-in-human Phase I clinical trial with…

Pre-clinical data show that NOP receptor agonists have the potential to act as potent analgesics without abuse liability.1 Leveraging the clinical data Grünenthal obtained during the development of its NOP receptor programme, Grünenthal now brings forward a candidate that shows best-in-class potency and selectivity for the NOP receptor. These properties are predicted to provide robust pain relief in a broad range of chronic pain indications without the serious central nervous system related side…
PR Newswire
22/10/2024

Biogen Announces Late Breaker and New Data Presentations at American Society of…

Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study of felzartamab for IgA nephropathyAdditional oral presentation to examine the impact of felzartamab on key disease-relevant biomarkersFelzartamab, an investigational anti-CD38 monoclonal antibody, is a potential first-in-class therapeutic candidate for a range of rare immune-mediated indications with planning underway for Phase 3 developmentCAMBRIDGE, Mass., Oct.22, 2024(GLOBE NEWSWIRE) --Biogen...
Nasdaq GlobeNewswire
22/10/2024

Cheshire and Merseyside Health and Care Partnership Secure Patient Care with…

"Cynerio delivered exactly what we needed: comprehensive visibility into all networked medical devices across our ICS trusts. Deployment was efficient, and the vendor's support was consistently responsive, helping us enhance our security posture and fortify our cybersecurity defences." said Matt Connor, Chief Digital Information Officer at Liverpool Womens Hospital NHS Foundation Trust. "Cynerio delivered exactly what we needed: comprehensive visibility into all networked medical…
PR Newswire
22/10/2024

Gradient Denervation Technologies Appoints Stanton Rowe to Board of Directors…

Serial entrepreneur and medical device industry executive adds key experience to board of directors Rowe has developed multiple innovative medical technologies through his current incubator, Nidus Biomedical, and with his prior incubator, NXT Biomedical. He served as Chief Scientific Officer of Edwards Lifesciences and was co-founder and CEO of Percutaneous Valve Technologies, the developer of the first transcatheter aortic valve replacement device which was later acquired by Edwards...
Nasdaq GlobeNewswire
22/10/2024

Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals

Because 99mTc and 188Re can each be produced using on-site generators, they enable a highly-differentiated solution for regions with limited radiopharmaceutical manufacturing infrastructure or dispersed populations. 99mTc enables imaging of patients with widely available SPECT scanners, while 188Re has demonstrated potential as a therapeutic isotope, thanks to its high-energy beta emission that maximises damage to tumour cells. Its short half-life (16.9 hours) also has the potential to simplify…
PR Newswire
22/10/2024

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of…

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn's disease and ulcerative colitisThe FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection in April 2024SELARSDI's U.S. launch for all indications is expected in Q1 2025 REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct.22, 2024(GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and...
Nasdaq GlobeNewswire
22/10/2024

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of…

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn's disease and ulcerative colitisThe FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection in April 2024SELARSDI's U.S. launch for all indications is expected in Q1 2025Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd...
Nasdaq GlobeNewswire
22/10/2024

KFSHRC Leads the Kingdom's Position on the Global Medical Tourism Map

Providing Care to International Patients from 17 Countries Worldwide RIYADH, Saudi Arabia, Oct.22, 2024(GLOBE NEWSWIRE) -- With the growing global interest in medical tourism, the Kingdom's healthcare sector strives to solidify its position as a distinguished hub for advanced medical treatments, transitioning from being a provider of outbound medical tourism to attracting 5% of the global patients who seek treatment abroad. Leading this initiative is King Faisal Specialist Hospital...
Nasdaq GlobeNewswire
22/10/2024

Oblique Therapeutics announces that NaV 1.8 project is advancing to next stage

"In the scientific community there is a general agreement that TRPV1 and NaV 1.8 are the two most promising targets for new treatments against chronic pain. I'm therefore pleased that we have reached this important milestone in our NaV 1.8 project that was only started in the late spring this year. I'm convinced that our advanced TRPV1 program with two highly promising classes of molecules together with the NaV 1.8 project will position Oblique Therapeutics among the leaders in the pain…
PR Newswire
22/10/2024

Rowenta, a brand of Groupe SEB, and Narwal Unveil Co-Engineered X-CLEAN 10 in…

As the world reference in small domestic equipment, Groupe SEB has a unique portfolio of top brands including Rowenta, Tefal, WMF and Krups… Rowenta, which celebrates 140 years of excellence this year, is one of its flagship brands and continues to drive innovation in household appliances. Rowenta's success has been bolstered by its presence within Groupe SEB's diverse ecosystem, allowing it to thrive in key categories such as Personal Care, Home Comfort, Linen Care and Floor Care, depending on…
PR Newswire
22/10/2024

World Psoriasis Day 2024: Psoriatic Disease and Family--Standing Together in…

The report highlights how psoriatic disease disrupts routines, increases household responsibilities, and alters leisure activities. Families find themselves navigating practical and emotional challenges together, often without adequate support. This report emphasizes the vital but often unrecognized role that family members play in managing the disease—offering care during flare-ups and emotional reassurance while grappling with their own feelings of helplessness and frustration. The report...
PR Newswire
22/10/2024

EBC 24 – Conference Programme Unveiled

Europe's leading business and discussion forum within the global bioplastics sector, the European Bioplastics Conference (EBC 24), has just released its programme. The conference will be held on 10-11 December 2024, in Berlin and online, bringing together industry leaders, innovators, and experts to share insights on the latest advancements in bioplastics.The first session will focus on key policy factors shaping the bioplastics industry and will be opened with a keynote by Kristin...
Nasdaq GlobeNewswire
22/10/2024

Ariceum Therapeutics Presents Outstanding Data on its First-in-Class…

Results demonstrate that 225Ac-satoreotide shows the strongest anti-tumoural effect in vivo at a low single dose when evaluating satoreotide and DOTA-TATE radiolabelled with different radionuclides. Irrespective of the radionuclides used, satoreotide demonstrated a higher pre-clinical anti-tumour efficacy when compared to DOTA-TATE which was less potent and required increased dose levels. Satoreotide was well tolerated across all dose levels and with all used radionuclides. These comparisons…
PR Newswire
22/10/2024

University hospitals in the UK join Homerton Healthcare's public cloud service…

"We cooperate extensively with Homerton to ensure the patients in our region receive timely care, and therefore see huge benefits of further facilitating that collaboration. By having a joint Sectra solution, our radiologists will have immediate access to each other's images and patient data, which will make it easier for us to collaborate around patient cases," says David Newey, Interim Chief Digital Transformation Officer at BHRUT. "We cooperate extensively with Homerton to…
PR Newswire
22/10/2024

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the…

stannual congress, that will take place on October 22-25, 2024, in Roma, Italy.The data will be presented in two posters: Controlling C-to-T editing with TALE base editorsPresenter:Alexandre Juillerat, Ph.D., Vice-President Gene Editing & NY Lab Head at Cellectis Date/Time:Thursday, October 24 from 2:00pm to 3:30pm CET Poster number:P0666 TALE base editors (TALEB) are fusions of a transcription activator-like effector domain (TALE), split-DddA deaminase halves,...
Nasdaq GlobeNewswire
22/10/2024

Embla Medical hf: Interim Report Q3 2024

22 October 2024 22 October 2024 COPENHAGEN, Denmark , Oct. 22, 2024 /PRNewswire/ -- Sveinn Sölvason, President and CEO, comments: "We delivered solid sales in the third quarter amounting toUSD 214 million. Organic sales growth was 7% and local currency growth was 11%. The strong momentum we have seen in EMEA throughout 2024 continued driven by strong performance in Prosthetics & Neuro Orthotics and Patient Care. In our Bracing & Supports business growth was...
PR Newswire
22/10/2024

Crossject reports strong manufacturing progress with its epilepsy rescue therapy…

Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file for EUA early next year and to receive a positive FDA response shortly thereafterCrossject will manufacture additional product batches, including first commercial batches in early 2025, in anticipation of first BARDA deliveries later that yearDijon, France, October 22 2024 (07:30 CET)...
Nasdaq GlobeNewswire
22/10/2024

Tecan's Capital Markets Day highlights strategic growth drivers, groundbreaking…

Tecan's Capital Markets Day highlights strategic growth drivers, groundbreaking innovation and product launches Männedorf, Switzerland, October 22, 2024– The Tecan Group (SIX Swiss Exchange: TECN) is hosting a Capital Markets Day, including a live webcast, today in Männedorf, Switzerland, providing investors with an in-depth view of the company's solid foundations for continued growth and profitability improvements. The strategic growth drivers that enable the company to capitalize on...
Nasdaq GlobeNewswire
22/10/2024

BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of…

Global 600 patient studywillevaluateefficacyand safetyofrecombinanthumanplasmagelsolin (rhu-pGSN)formoderate-to-severeARDS.Rhu-pGSN is an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Endogenous levels plummet in ARDS, correlating with disease severity. NORTH BRUNSWICK, N.J., Oct.22, 2024(GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the...
Nasdaq GlobeNewswire
22/10/2024

Global Antibody-Drug Conjugate Market Set for a ~USD 26 Billion Surge by 2030 |…

Key Takeaways from the Antibody-drug Conjugate Market Report Key Takeaways from the Antibody-drug Conjugate Market Report To read more about the latest highlights related to the ADC market, get a snapshot of the key highlights entailed in the Global Antibody-drug Conjugate Market Report Antibody-drug Conjugate Overview Antibody-drug conjugates (ADCs) represent a promising class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the potent...
PR Newswire
21/10/2024

/C O R R E C T I O N -- Global Health Exhibition/

During the opening ceremony, the Minister of Health, His Excellency Fahd bin Abdurrahman Al-Jalajel, highlighted the impact of health transformation in the sector, stating: "We aim to position Saudi Arabia as a hub for addressing current and future global challenges, following a unified government approach under Vision 2030. This is based on the principle of 'health in all policies' by developing regulations that encourage investment in innovation, building a healthcare system that…
PR Newswire
21/10/2024

Global Health Exhibition Opens in Riyadh With SAR 50 Billion Announced in…

He added, "Today, we are proud of the World Health Organization's recognition of Saudi Arabia's elimination of trans fats from food products, placing the Kingdom at the forefront of countries receiving this distinction. Additionally, the WHO has announced that Saudi Arabia, represented by the Saudi Food and Drug Authority, is the first country in the region to achieve the highest 'maturity level 4' in the regulation of medicines and vaccines." He added, "Today, we are proud of the…
PR Newswire
21/10/2024

Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in…

Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentumDIAMOND program committees expanded with globally renowned retina expertsIf approved, OCS-01 has the potential to transform the treatment paradigm as the first topical eye drop to treat DMEOculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces the acceleration...
Nasdaq GlobeNewswire
21/10/2024

Antibody-Drug Conjugates Market to Grow at 28.4% CAGR from 2024 to 2029

ADCs are at the forefront of precision medicine, offering high specificity for cancer cells while minimizing toxicity. With 13 commercially available products globally and more than 200 in clinical trials, ADC development has become one of the most attractive classes of biological drugs. Significant investment in research and development by pharmaceutical and biotech companies and the increasing number of ADCs in clinical trials are important drivers of the ADC market. ADCs are at the…
PR Newswire
21/10/2024
Altri  Comunicati